相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds
Mohamed Elmeliegy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
Tycho Heimbach et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
Christian Rolfo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Burden of liver diseases in the world
Sumeet K. Asrani et al.
JOURNAL OF HEPATOLOGY (2019)
Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling
Jan Snoeys et al.
CLINICAL PHARMACOKINETICS (2017)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group
Stuart M. Lichtman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation
Diane D. Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
CD38-mediated Ca2+ signaling contributes to glucagon-induced hepatic gluconeogenesis
So-Young Rah et al.
SCIENTIFIC REPORTS (2015)
Infiltration of inflammatory cells expressing mitochondrial proteins around bile ducts and in biliary epithelial layer may be involved in the pathogenesis in primary biliary cirrhosis
Motoko Sasaki et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Liver fibrosis and repair: immune regulation of wound healing in a solid organ
Antonella Pellicoro et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Stephen I. Shibata et al.
CLINICAL CANCER RESEARCH (2013)
Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
J. Sarantopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity
Dhanashri Kolwankar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Liver disease selectively modulates cytochrome P450-mediated metabolism
Reginald F. Frye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
AP Venook et al.
ANNALS OF ONCOLOGY (2003)
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565
AP Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
